<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260425069152N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-17</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of a new generation rotational prosthesis compared to a standard prosthesis in primary arthroplasty</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of a new generation rotational prosthesis compared to a standard prosthesis in primary arthroplasty of severely deformed knees: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/93823</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To achieve equal numbers of participants in the study groups and minimize differences in group sizes, randomization will be performed using permuted block randomization with fixed block sizes of four and a 1:1 allocation ratio.

For this purpose, the randomization blocks and allocation sequences will be generated using the Sealed Envelope online randomization service. The allocation sequences will be placed in sequentially numbered, sealed opaque envelopes. Upon enrollment of eligible participants, the envelopes will be opened sequentially according to the predetermined order, and each participant will be assigned to one of the study arms based on the allocation sequence contained in the corresponding envelope.

Random allocation of eligible participants will be performed by an individual who is independent of the research team and will have no involvement in the treatment, participant follow-up, data collection, or data recording processes, Blinding description: This study will be double-blinded with respect to the participants and outcome assessors. Participants will be allocated to the intervention or control group according to the predetermined randomization sequence generated using block randomization. Participants will not be informed of the type of prosthesis used, and the outcome assessors will be blinded to participants’ group allocation.

Due to the nature of the intervention, the surgeon and members of the surgical team responsible for selecting and implanting the prosthesis cannot be blinded to treatment allocation.

If the statistical analysis is performed by an independent statistician, the data from the two groups will be provided using anonymous group codes (e.g., Group A and Group B), allowing the statistical analysis to be conducted without knowledge of the type of prosthesis assigned to each group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>**Severe Knee Osteoarthritis with Knee Deformity**.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients will undergo total knee arthroplasty using a domestically manufactured rotating-hinge knee prosthesis (Osveh Company). Intervention 2: Control group: **Patients receiving a routinely used imported knee prosthesis.**.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Additional data doesn't exist</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sanaz Zabihi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Orthopedis Research Center, Ghaem Hospital, Ahmad Abad Blvd</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>000000000</zip>
        <telephone>+98 51 3841 7453</telephone>
        <email>sanaz.zabihi1999@gmail.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Hossein Ebrahimzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahmad Abad, Ghaem Hospital</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>0000000000</zip>
        <telephone>+98 51 3841 7453</telephone>
        <email>Ebrahimzademh@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of primary or secondary knee osteoarthritis with severe deformity, defined as varus deformity &gt;15°, valgus deformity &gt;20°, or a flexion contracture &gt;30°
Clinically significant instability of the collateral ligaments (MCL or LCL), as confirmed by the treating surgeon
Failure of conservative treatment, accompanied by severe pain and functional limitations
Provision of written informed consent to participate in the study</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Acute or emergency knee surgery.
History of localized or systemic knee infection.
History of previous knee surgery.
Uncontrolled underlying medical conditions, such as diabetes mellitus (which may lead to impaired immune function), neuromuscular disorders affecting lower-extremity function (e.g., severe peripheral neuropathy or sequelae of stroke), severe renal impairment (eGFR &lt;30 mL/min), or severe systemic diseases that would place the patient at high risk during surgery.
Patients with immunodeficiency.
Severe bone loss requiring the use of bulk structural bone grafts or specialized augments beyond what can be managed with standard prosthetic components.
Body mass index (BMI) &gt;40 kg/m².
Known allergy to any of the prosthetic components or materials (e.g., titanium, polyethylene, etc.).
Unwillingness or inability to attend regular follow-up visits.
Injury occurring during the follow-up period due to causes unrelated to the treatment.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients will undergo total knee arthroplasty using a domestically manufactured rotating-hinge knee prosthesis (Osveh Company).</i_keyword>
      <i_keyword>Control group: **Patients receiving a routinely used imported knee prosthesis.**</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>(knee surgery score -KSS). Timepoint: At baseline, and 2, 4, and 6 months after surgery. Method of measurement: Using the Knee Society Score (KSS) questionnaire.</prim_outcome>
      <prim_outcome>Surgical site infection. Timepoint: At baseline, and 2, 4, and 6 months after surgery. Method of measurement: **Clinical assessment**.</prim_outcome>
      <prim_outcome>Quality of life. Timepoint: At baseline, and 2, 4, and 6 months after surgery. Method of measurement: SF-12 Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Revision rate. Timepoint: 6 months post surgery. Method of measurement: clinical assessment.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Osveh Asia Medical Instruments Company</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-08-10</approval_date>
        <contact_name>Ethics Committee of Imam Reza Hospital</contact_name>
        <contact_address>Imam Reza Educational, Research and Medical Center, Imam Reza Hospital Square, Ibn Sina Street, Mashhad, Razavi Khorasan, Iran Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
